Fresenius Medical Expects Smaller Annual Income Decline Amid Easing Cost Inflation, Labor Shortages

Fresenius Medical Care AG's FMS Q2 adjusted operating income increased 41% Y/Y to €401 million. The adjusted net income jumped 51% to €175 million.

Revenue increased by 1% to €4.83 billion in the second quarter (+6% at constant currency, +6% organic).

Care Delivery revenue increased by 1% to €3.87 billion (+6% at constant currency, +6% organic).

In parallel, the company continuously executes its operational efficiency and turnaround plans. The FME25 transformation program delivered €75 million in additional savings in the second quarter. 

Fresenius Medical Care is fully on track to achieve sustainable savings of €250-300 million by year-end 2023 and €650 million by year-end 2025.

"As expected, we have seen a stabilization of the labor market and the inflationary environment. Our measures to increase productivity, supported by the targeted clinic closures, are driving a positive development. This gives us the confidence to narrow our operating income guidance range to the upper part for the year," said Helen Giza, CEO of Fresenius Medical Care.

Guidance: Fresenius Medical Care expects 2023 operating income to remain flat or slip by up to a low-single-digit percentage. The company had previously projected earnings to remain flat or decline by up to a high-single-digit percentage rate.

The company's target to achieve an operating income margin of 10%-14% by 2025 remains unchanged.

Price Action: FMS shares are down 2.01% at $25.31 on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!